Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109310 | 0.94 | TSHR (0.51) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL25109274 | 0.94 | TSHR (0.51) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL25110402 | 0.94 | TSHR (0.51) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL26375472 | 0.88 | MEN1 (0.47) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL25109494 | 0.87 | HPGD (0.46) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL25109749 | 0.87 | HPGD (0.46) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL22473740 | 0.85 | MEN1 (0.42) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23334540 | 0.84 | TSHR (0.51) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL18707764 | 0.84 | HPGD (0.48) | TSHRHPGDMEN1KMT2ACNR1 | |
| SCHEMBL20022933 | 0.84 | TSHR (0.59) | TSHRHPGDMEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | TSHR 4066/4885HPGD 3995/4885MEN1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.